An interventional study of Levetiracetam and Valproic acid in Status Epilepticus, sponsored by RESnTEC, Institute of Research. Completed at 1 site in Pakistan. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2025-07-04.
Sponsored by RESnTEC, Institute of Research · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing levetiracetam in Status Epilepticus — 2 open to participants now, 2 under way, 1 of them phase 3. Levetiracetam · Status Epilepticus.
Among the 13 studies testing levetiracetam in Status Epilepticus, this one is the 7th largest by enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 11th registered.
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
Browse Status Epilepticus studies →2 of the 13 studies testing levetiracetam in Status Epilepticus are open now, in 2 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 1+
Ministry of Health and Sports, Myanmar · Sites in Burma
Ages 1 mo–12 yrs
By country, each count listing its studies:
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 138 is above the median of 80 across 75 interventional studies indexed under Status Epilepticus.
Median enrollment 138 across the 13 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 10 most frequent:
RESnTEC, Institute of Research is the lead sponsor of 16 studies on the registry; 2 are open to participants now.
RESnTEC, Institute of Research has 1 study filed under Status Epilepticus — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing levetiracetam in Status Epilepticus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since there is a significant degree of variability in the results of previous studies and there exists a thirst for local data regarding this topic, the current study was planned, with the objective of comparing the efficacy of levetiracetam versus valproic acid in pediatric patients with status epilepticus.
Early and sustained control of seizures is paramount in status epilepticus to save the life of the patient, and this warrants the use of the best drug based on evidence. Identifying a better drug in status epilepticus would add to the local data and help clinicians in making evidence-based decisions to opt for an appropriate treatment in case of failed response to benzodiazepines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this group, patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
Drug: Levetiracetam
Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
Drug: Valproic acid
Patients were treated with intravenous levetiracetam (LEV) 20 mg/kg over 15 minutes, followed by 60 mg/kg/day in two divided doses over 24 hours.
Patients received intravenous valproic acid at 15 mg/kg over 15 minutes, followed by 20 mg/kg/day in two divided doses over 24 hours.
Sustained control of seizure activity
Sustained control was labeled when there was no seizure activity on EEG and regain of consciousness for ≥ 24 hours
Time frame: 24 hours
Immediate cessation of seizure activity
Immediate cessation was defined as cessation of seizure activity within 15-30 minutes, after completion of drug infusion.
Time frame: 30 minutes
Plan to share: No — Data can be shared on a reasonable request.
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Apr 2025, 5 months.
Of 22 interventional studies with no phase under Status Epilepticus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 65. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levetiracetam · Valproic Acid
RESnTEC, Institute of Research